H. Januszewicz

发表

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, R. Hicks, M. MacManus, 2002, The American journal of medicine.

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure

Ashley P Ng, A. Hogg, R. Hicks, 2007, Leukemia & lymphoma.

A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma

B. Dale, J. Matthews, J. Biagi, 2005, Leukemia & lymphoma.

[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.

R. Hicks, H. Prince, J. Seymour, 2008, Clinical lymphoma & myeloma.

Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

R. Herrmann, P. Browett, A. Schwarer, 2004 .

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.

H. Prince, J. Seymour, M. Wolf, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

J. Matthews, A. Schwarer, D. Gill, 2001, Leukemia.

Peripheral blood CD34+ cell count reliably predicts autograft yield

I. Bertoncello, M. Wolf, H. Prince, 1998, Bone Marrow Transplantation.

Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

R. Hicks, H. Prince, S. Harrison, 2013, British Journal of Cancer.

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

R. Johnstone, S. Harrison, J. Seymour, 2011, Blood.

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

C. Tam, H. Prince, S. Harrison, 2014, Annals of Hematology.

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

H. Prince, J. Seymour, G. Kennedy, 2003, European journal of haematology.

The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.

H. Prince, J. Seymour, D. Ritchie, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.

M. Millward, J. Matthews, D. Rischin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose chemotherapy and autologous bone marrow transplantation in advanced Hodgkin's disease

A. Dodds, M. Wolf, I. Cooper, 1992, The Medical journal of Australia.

Prognostic markers of disease activity in Hodgkin's disease.

K. Yuen, J. Matthews, M. Wolf, 1998, Leukemia & lymphoma.

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

K. Yuen, R. Johnstone, S. Harrison, 2008 .

Local experience with the novel human anti‐CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia

C. Cheah, J. Seymour, D. Carney, 2012, Internal medicine journal.

Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF

B. Ma, J. Seymour, M. Slavin, 2001, Leukemia & lymphoma.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.

D. Westerman, H. Quach, H. Januszewicz, 2005, Haematologica.

Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.

J. Bashford, A. Grigg, P. Mollee, 1999, Leukemia research.

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

C. Tam, M. Lasica, J. Butler, 2019, Leukemia & lymphoma.

Spinal epidural lipomatosis in myeloma

S. Alatakis, M. Bishton, M. Liew, 2007, Leukemia & lymphoma.

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.